f6k_071315.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
________________
 
FORM 6-K
________________
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
August 10, 2015
________________
 
NOVO NORDISK A/S
 (Exact name of Registrant as specified in its charter)
 
 
Novo Allé 
DK- 2880, Bagsvaerd 
Denmark
(Address of principal executive offices)
________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
 
Form 20-F [X]     
     Form 40-F [  ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes [  ]     
      No [X]
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
 
 

Novo Nordisk A/S – Share repurchase programme

 

Bagsværd, Denmark, 10 August 2015 – On 30 April 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.

 

Under the programme initiated 30 April 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 9.3 billion in the period from 30 April 2015 to 27 October 2015.

 

Since the announcement as of 3 August 2015, the following transactions have been made under the programme:

 

 
Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement

12,277,200

  

4,675,387,896

3 August 2015

185,000
406.15
75,137,380

4 August 2015

190,000
407.71
77,464,102

5 August 2015
170,000

409.68

69,646,314

6 August 2015

195,000
400.76
78,148,220

7 August 2015

195,000
390.96
76,237,571
       
Accumulated under the programme
13,212,200
  
5,052,021,482

 

With the transactions stated above, Novo Nordisk owns a total of 33,001,891 B shares of DKK 0.20, corresponding to 1.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a 12-month period beginning 30 January 2015. As of 7 August 2015, Novo Nordisk has

 
 

 
Page 2 of 2

 

repurchased a total of 24,390,104 B shares equal to a transaction value of DKK 8,752,021,152.

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

 
 
Further information
Media:

Anne Margrethe Hauge

+45 3079 3450
amhg@novonordisk.com
     
Investors:
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Daniel Bohsen
+45 3079 6376
dabo@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com
Frank Daniel Mersebach (US)
+1 609 235 8567
fdni@novonordisk.com
  
 
 
 
 
 
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
 
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
       
   
Company announcement No 48 / 2015
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
 
Date: August 10, 2015
 
NOVO NORDISK A/S
 
Lars Rebien Sørensen,
Chief Executive Officer